Table 1.
Summary of the selected studies
| First Author | Title | Publication year | Type of study | Country | Study period |
|---|---|---|---|---|---|
| Jandourek et al. [9] | Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia | 2014 | Clinical Trial | USA | Jul 2007-Dec 2008 |
| File et al. [10] | FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia | 2011 | Clinical Trial | USA | Jan 2008-Dec 2008 |
| Low et al. [11] | FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia | 2011 | Clinical Trial | USA | Jul 2007-Aug 2008 |
| Shorr et al. [12] | Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials | 2013 | Clinical Trial | USA | Jul 2007-Dec 2008 |
| File et al. [13] | Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus. Ceftriaxone in patients with community-acquired pneumonia | 2010 | Clinical Trial | USA | Jul 2007-Dec 2008 |
| Zhong et al. [14] | Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial | 2015 | Clinical Trial | China, India, South Korea, Taiwan, Vietnam | Dec 2011-Apr 2013 |
| Arshad et al. [15] | Ceftaroline fosamil for treatment of Methicillin-Resistant Staphylococcus aureus hospital-acquired pneumonia and health care-associated pneumonia. A 5-year matched case-control evaluation of epidemiology and outcomes | 2016 | Case-control study | USA | Jan 2009-May 2013 |
| Eckburg et al. [22] | Day 4 Clinical response of ceftaroline fosamil versus ceftriaxone for community-acquired bacterial pneumonia | 2012 | Retrospective integrated analysis of FOCUS trials | USA | Jul 2007-Dec 2008 |
| Guervil et al. [16] | Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP) | 2015 | Retrospective Cohort study | USA | Aug 2011-Feb 2013 |
| Udeani et al... [17] | Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients | 2014 | Retrospective Cohort study | USA | Aug 2011-Ap 2013 |
| Ramani et al..... [18] | Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experienc | 2014 | Retrospective Cohort study | USA | Aug 2011-Feb 2013 |
| Vasquez et al... [19] | Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia | 2015 | Retrospective Cohort study | USA | Aug 2011-Feb 2013 |
| Casapao et al... [20] | Large retrospective study evaluation of the effectiveness and safety of Ceftaroline fosamil therapy | 2014 | Retrospective observational study | USA | Jan 2011-Jun 2013 |
| Kaye et al. [21] | Ceftaroline fosamil for the treatment of hospital acquired pneumonia and ventilator associated pneumonia | 2015 | Retrospective Cohort study | USA | Sep 2013-Mar 2014 |